The purpose of this study is to investigate safety and toleration of multiple inhaled doses as well as the time course of PF-03526299 concentration in the blood following dosing by dry powder inhaler.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
24
dry powder for inhalation, 1.396 mg, BID for 14 days
dry powder for inhalation, 4 mg, BID for 14 days
Pfizer Investigational Site
Singapore, Singapore
Safety/toleration: Adverse events, vital signs, 12 lead ECG, blood and urine safety tests and physical examination.
Time frame: 17 days
Pharmacokinetic parameters: Plasma Day 1: Cmax, Tmax, AUCτau.
Time frame: Day 1 - 17
Plasma Day 7: Cmax, Tmax.
Time frame: 7 Days
Plasma Day 14: Cmax, Tmax, CL/F, AUCτau, t½, accumulation ratio, time to steady state.
Time frame: 14 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.